UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) has secured a major contract with the U.K. to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK Plc (NYSE:GSK). The contract includes over 3.5 million doses for older adults and 1.4 million doses for pregnant mothers over the next two years. This decision is a significant blow to GSK, which is in fierce competition with Pfizer in the RSV vaccine market.
June 24, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GSK has lost a major contract to Pfizer for the supply of RSV vaccines to the U.K., which is a significant setback in the competitive RSV vaccine market. GSK's Arexvy vaccine, which is only approved for older adults, was outperformed by Pfizer's Abrysvo in the tender process.
Losing the U.K. contract to Pfizer is a significant blow to GSK, impacting its market share and revenue potential in the RSV vaccine market. The decision underscores the competitive challenges GSK faces.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Pfizer has secured a significant contract with the U.K. for its Abrysvo RSV vaccine, which includes over 3.5 million doses for older adults and 1.4 million doses for pregnant mothers over the next two years. This contract is a major win for Pfizer in the competitive RSV vaccine market.
The contract win is a significant boost for Pfizer, enhancing its market position in the RSV vaccine segment. The large volume of doses and the inclusion of pregnant mothers highlight the importance of this deal.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100